About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Clinicaltrials.gov identifier NCT03932201

Recruitment Status Recruiting

First Posted April 30, 2019

Last update posted February 18, 2021

Study Description

Brief summary:

The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.

  • Condition or Disease:Hemophilia A
  • Intervention/Treatment: Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 200 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
  • Actual Study Start Date: October 2019
  • Estimated Primary Completion Date: June 2025
  • Estimated Study Completion Date: September 2025
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Previously treated patient (PTPs) with hemophilia A
Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Outcome Measures
  • Primary Outcome Measures: 1. Mean annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 12 month ]
  • 2. Mean annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 24 month ]
  • 3. Mean annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 36 month ]
  • 4. Median annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 12 month ]
  • 5. Median annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 24 month ]
  • 6. Median annualized number of reported total bleeds in patients with hemophilia A [ Time Frame: At 36 month ]
  • Secondary Outcome Measures: 1. Occurrence of AEs. [ Time Frame: Up to 36 months ]
    Adverse Events (AEs) includes: AEs of special interest, Adverse Event, Serious Adverse Event, Adverse reaction. AEs of special interest includes: hypersensitivity reactions, loss of drug effect, renal impairment, neurocognitive disorders, inhibitor development.
  • 2. Duration of AEs. [ Time Frame: Up to 36 months ]
  • 3. Treatment of AEs. [ Time Frame: Up to 36 months ]
  • 4. Severity of AEs. [ Time Frame: Up to 36 months ]
  • 5. Outcome of AEs. [ Time Frame: Up to 36 months ]
  • 6. Number of infusions and FVIII consumption to achieve hemostasis during surgery [ Time Frame: Up to 36 months ]
  • 7. Change in joint scores (HJHS) [ Time Frame: From baseline to 12 months, 24 months and 36 months ]
    HJHS:Hemophilia Joint Health Score
  • 8. Joint status evaluation by ultrasound (HEAD-US score), if available or part of standard clinical practice. [ Time Frame: Up to 36 months ]
    HEAD-US:Hemophilia Early Arthropathy Detection with Ultrasound
  • 9. Change of number of affected joints by patient [ Time Frame: From baseline to 12 months, 24 months and 36 months ]
    Target joint is defined as a joint in which ≥3 spontaneous bleeds have occurred within a consecutive 6-month period
  • 10. Annualized number of spontaneous, joint, and trauma bleeds. [ Time Frame: At 12 month, 24 month and 36 month ]
  • 11. Number of reported bleeds during the study compared with number of reported bleeds for previous FVIII products in the 12 months prior to enrollment into the study. [ Time Frame: Up to 36 months ]
    Bleeds includes total, spontaneous, joint, and trauma.
  • 12. Proportion of patients with 0 bleeds, and the difference in proportion comparing to previous prophylaxis treatment. [ Time Frame: Up to 36 months ]
  • 13. Cmax for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
    Cmax: Maximum plasma Concentration
  • 14. AUC for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
    AUC:Area under the plasma concentration versus time curve
  • 15. Half-life [t½] for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
  • 16. FVIII trough for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
  • 17. FVIII peak levels for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
  • 18. In-vivo recovery for previous FVIII products versus damoctocog alfa pegol. [ Time Frame: Up to 36 months ]
  • 19. Date of bleeding event of treatment of break-through bleeds. [ Time Frame: Up to 36 months ]
  • 20. Reason for infusion and location of bleed of treatment of break-through bleeds. [ Time Frame: Up to 36 months ]
  • 21. Date of treatment of break-through bleeds. [ Time Frame: Up to 36 months ]
  • 22. Number of infusions and dose per infusion for each bleeding event of treatment of break-through bleeds. [ Time Frame: Up to 36 months ]
  • 23. Changes of Hemo-SAT A score [ Time Frame: From baseline to 12 months, 24 months and 36 months ]
    Hemo-SAT A:Hemophilia Treatment Satisfaction Questionnaire for adults。The Hemo-SAT questionnaire version for adults (Hemo-SAT A) consists of 34 items pertaining to 6 dimensions (Ease & Convenience, Efficacy, Burden, Specialist/Nurses, Center/Hospital, General Satisfaction).
  • 24. Changes of Hemo-QoL (A and SF) score [ Time Frame: From baseline to 12 months, 24 months and 36 months ]
    Hemo-QoL-A:Hemophilia Quality of Life Measure for adults Hemo-QoL-SF:Hemophilia Quality of Life short form for children Hemo-QoL-A is a hemophiliaspecific quality of life questionnaire for adults aged 18 years and above. The questionnaire has 41 items covering 6 domains: Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Impact, and Treatment Concerns. For patients younger than 18 years, the Hemo-QoL-SF Questionnaire for children and adolescents (12 to 17 years) is used. The Hemo-QoL-SF contains 35 questions covering 9 domains: Physical Health, View of Yourself, Family, Friends, Others, Sports, Dealing, and Treatment.
  • 25. Changes of WPAI score [ Time Frame: From baseline to 12 months, 24 months and 36 months ]
    WPAI:Work Productivity and Activity Impairment Scale。 Scores are expressed as percentages of impairment/ productivity loss, with higher scores indicating greater impairment.
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prop hylaxis, or intermittent prophylaxis).
Criteria

Inclusion Criteria:

- Diagnosis of hemophilia A.

- Patients previously treated for Hemophilia A.

- Patients without previous history of inhibitors or patients with previous history of
inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry.

- No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor.

- Initiation of or currently on damoctocog alfa pegol with any kind of treatment
modality (on-demand, prophylaxis, or intermittent prophylaxis).

- Signed informed consent/assent.

Exclusion Criteria:

- Concurrent participation in an investigational program with interventions outside of
routine clinical practice.

- Diagnosis of any other bleeding/coagulation disorder other than hemophilia A.

- Contra-indications according to the local marketing authorization.

- Patient on immune tolerance induction (ITI) treatment at the time of enrollment.

Contacts and Locations
Contacts

Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com

Contact: For trial location information (Phone Menu Options '3' or '4') (+)1-888-84 22937

Locations
Show 34 Study Locations
Sponsors and Collaborators

Bayer

More Information
  • Responsible Party: Bayer
  • ClinicalTrials.gov Identifier: NCT03932201 History of Changes
  • Other Study ID Numbers: 20002
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: February 18, 2021
  • Last Verified: February 2021
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Hemophilia A